A genetic mutation that blocks vitamin absorption in the heart causes early-onset heart disease, but Gram Research analysis shows that vitamin supplementation—specifically biotin and pantothenic acid—can completely prevent the disease when started early. In a 2026 study, mice with this mutation developed severe heart failure by 26 weeks, but those receiving vitamin supplementation from before birth had completely normal hearts and survived normally. One patient with this mutation who received early vitamin treatment avoided needing a heart transplant.
Researchers discovered that a genetic mutation affecting how the heart absorbs two essential vitamins—biotin and pantothenic acid—can cause serious heart disease in children. Using mice and studying real patients, scientists found that hearts without this vitamin-transport gene developed progressive damage and failure. The exciting news: giving these vitamins early, even before birth, completely prevented heart disease in the mouse model. One patient who received early vitamin treatment avoided needing a heart transplant, while another without treatment required one. This research suggests that vitamin supplementation could be a life-saving treatment for people with this rare genetic heart condition.
Key Statistics
A 2026 research study found that mice with a defective SLC5A6 gene developed progressive heart disease and died prematurely at 26 weeks of age, but vitamin supplementation from preconception onwards completely prevented cardiac dysfunction and preserved normal survival.
According to research reviewed by Gram, early vitamin supplementation with biotin and pantothenic acid prevented heart disease in 100% of treated mice with SLC5A6 mutations, compared to progressive cardiac failure in all untreated mice.
A case study of two patients with SLC5A6 mutations showed that the patient who received early vitamin treatment avoided heart transplantation, while the patient without early treatment required a transplant, demonstrating the clinical potential of early intervention.
The Quick Take
- What they studied: Whether a genetic mutation that blocks vitamin absorption in the heart causes heart disease, and whether giving vitamins can prevent or treat it.
- Who participated: Two families with the genetic mutation who had children with early heart disease, plus laboratory mice genetically engineered to have the same mutation.
- Key finding: Mice without the vitamin-transport gene developed severe heart disease by 26 weeks of age, but vitamin supplementation starting before birth completely prevented the disease and extended survival.
- What it means for you: If you or a family member has been diagnosed with early-onset heart disease without a clear cause, genetic testing for this mutation might reveal a treatable condition. Early vitamin supplementation could potentially prevent or reverse heart damage. However, this is a rare condition, and you should discuss genetic testing with your cardiologist.
The Research Details
Scientists started by finding two families whose children had unusual early-onset heart disease caused by mutations in a gene called SLC5A6. This gene normally helps heart cells absorb two vitamins—biotin and pantothenic acid—that are crucial for energy production inside cells. To understand how this mutation causes heart disease, researchers created laboratory mice with the same genetic defect specifically in their heart cells. They then tracked these mice over time, measuring heart function using imaging and electrical tests, and examined heart tissue under microscopes. Finally, they tested whether giving the missing vitamins could prevent or reverse the disease. The research team also followed the clinical outcomes of the two patients with this mutation—one who received early vitamin treatment and one who did not.
This research approach is important because it bridges the gap between rare genetic diseases in humans and understanding the underlying biology. By studying both patients and mice with the same mutation, researchers could prove that the vitamin defect directly causes heart disease and identify a potential treatment. This type of research is crucial for rare diseases because there aren’t enough patients to run large clinical trials, so animal models help establish cause-and-effect relationships.
This study has several strengths: it identifies a clear genetic cause in real patients, creates a mouse model that reproduces the human disease, uses multiple advanced imaging and testing methods to confirm findings, and shows that treatment works. The main limitation is the small number of human patients (two families), which is typical for rare genetic diseases. The mouse model strongly supports the human findings, and the fact that one patient improved with treatment provides real-world validation.
What the Results Show
Mice lacking the SLC5A6 gene in their heart cells developed progressive heart disease that worsened over time. By 8 weeks of age, before obvious heart problems appeared, the researchers detected early warning signs: heart cells were enlarged, scar tissue was forming, and the energy-producing structures inside cells (mitochondria) were not working properly. By 26 weeks, the mice had severe heart dysfunction and died prematurely. The heart imaging and electrical tests showed clear deterioration matching what doctors see in human heart disease patients. The most striking finding was that vitamin supplementation completely prevented this disease: mice that received biotin and pantothenic acid from before birth had normal hearts, normal heart function, and normal lifespans. This prevention worked even though the genetic defect was still present—the vitamins compensated for the broken transport system. In the human patients, one who received early vitamin treatment avoided needing a heart transplant, while the other patient without early treatment eventually required a transplant.
Detailed analysis of heart tissue revealed that the vitamin deficiency disrupted the production of Coenzyme A, a critical molecule that cells need to generate energy. This energy shortage caused heart cells to enlarge abnormally and triggered excessive scar tissue formation. The research also showed that these metabolic problems appeared very early—at 8 weeks in mice—before the heart showed obvious signs of failure, suggesting there’s a window of opportunity for early intervention before permanent damage occurs.
This research adds to growing evidence that metabolic problems (how cells produce and use energy) can cause heart disease, particularly in children. Previous studies suggested that vitamin deficiencies might affect heart health, but this is the first study to clearly prove that a specific vitamin-transport defect causes cardiomyopathy and that vitamin supplementation can prevent it. The findings align with other research showing that mitochondrial dysfunction—problems with cellular energy production—is an important cause of inherited heart disease.
The study involved only two human families, so we cannot yet know how common this genetic mutation is or whether it affects different people in different ways. The mouse model is helpful but may not perfectly replicate human disease. The study did not test whether vitamin supplementation could reverse heart disease that had already developed—only whether it could prevent it from starting. Long-term safety data on high-dose vitamin supplementation in humans is limited. Finally, this appears to be a rare genetic condition, so these findings may not apply to the much more common forms of heart disease.
The Bottom Line
For people with this specific SLC5A6 genetic mutation: Early vitamin supplementation with biotin and pantothenic acid appears highly effective at preventing heart disease (strong evidence from animal model and one patient case). For the general population: This research does not suggest that vitamin supplementation prevents common heart disease, as this is a rare genetic condition. If you have early-onset heart disease without a clear cause, ask your cardiologist about genetic testing for SLC5A6 mutations.
This research is most relevant to: families with a history of early-onset heart disease without an obvious cause, people who have been diagnosed with dilated cardiomyopathy in childhood or young adulthood, and genetic counselors or cardiologists evaluating rare heart disease cases. It is not relevant to people with common heart disease risk factors like high blood pressure, high cholesterol, or obesity.
In the mouse model, vitamin supplementation prevented disease development when started before birth. In the human patient case, early treatment prevented the need for a heart transplant. The timeline for benefits in newly diagnosed patients is unknown but likely depends on how early treatment begins and how much heart damage has already occurred.
Frequently Asked Questions
Can vitamin deficiency cause heart disease in children?
Yes, a specific genetic defect affecting vitamin absorption (SLC5A6 mutation) causes early-onset heart disease in children. Research shows that biotin and pantothenic acid deficiency leads to energy production problems in heart cells, causing progressive heart failure.
What vitamins prevent this type of heart disease?
Biotin and pantothenic acid supplementation prevents heart disease in people with SLC5A6 mutations. These vitamins are essential cofactors for cellular energy production. Early supplementation, ideally before birth or in infancy, appears most effective.
Is this genetic heart disease common?
No, SLC5A6-related heart disease is rare, identified in only two families so far. However, it represents an important example of how genetic metabolic defects cause heart disease and how targeted vitamin therapy can prevent it.
Should everyone take biotin and pantothenic acid supplements?
No, this research applies only to people with the specific SLC5A6 genetic mutation. The general population gets adequate biotin and pantothenic acid from normal diet. High-dose supplementation is only recommended for confirmed genetic cases.
Can vitamin supplements reverse heart disease that already developed?
This study showed prevention of heart disease with early supplementation, but did not test whether vitamins could reverse established heart damage. One patient who received early treatment avoided transplant, suggesting earlier intervention is better.
Want to Apply This Research?
- If you have this genetic condition and are taking vitamin supplementation, track your cardiac symptoms weekly: shortness of breath during normal activities, unusual fatigue, chest discomfort, or swelling in legs/ankles. Rate each symptom 0-10 to monitor improvement over months.
- Set daily reminders to take prescribed biotin and pantothenic acid supplements at the same time each day. Log each dose in the app to ensure consistent adherence, which is critical for preventing heart disease progression in this condition.
- Maintain a 6-month tracking log of scheduled cardiology appointments, echocardiogram results, and any changes in exercise tolerance or symptoms. Share this data with your cardiologist to assess whether vitamin supplementation is effectively preventing disease progression.
This research describes a rare genetic condition affecting vitamin transport in the heart. It is not applicable to common heart disease. If you have been diagnosed with early-onset heart disease without a clear cause, discuss genetic testing with your cardiologist before considering vitamin supplementation. Do not start high-dose vitamin supplementation without medical supervision, as safety and appropriate dosing depend on individual factors. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.